Shanghai Fudan Zhangjiang Bio Pharmaceutical : INSIDE INFORMATION-UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INSIDE INFORMATION

UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE

NINE MONTHS ENDED 30 SEPTEMBER 2019

This announcement is made by Shanghai Fudan-ZhangjiangBio-Pharmaceutical Co., Ltd.* (the "Company", together with its subsidiaries, the "Group") pursuant to Rule

13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcements of the Company dated 8 March 2019, 12 March 2019, 26 April 2019, 7 May 2019, 13 May 2019, 21 June 2019, 31 July 2019, 29 August 2019, 2 September 2019, 29 September 2019, 10 October 2019, 20 October 2019 and 27 October 2019, and the circulars of the Company dated 12 March 2019, 4 April 2019 and 6 June 2019 containing, among other things, related matters of the proposed initial public issue of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the "Shanghai Stock Exchange") by the Company (the "Proposed Issue of A Shares"). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circulars

The Company hereby announces that the board of the Company (the "Board") held a meeting on 31 October 2019, reviewed and approved the unaudited consolidated financial statements of the Group for the nine months ended 30 September 2019 which was compiled in accordance with the China Accounting Standards (the "Consolidated Financial Statements"). The Company may update the financial information in the prospectus for the Proposed Issue of A Shares (the "Prospectus") and submit to the Shanghai Stock Exchange in the near future. When the updated Prospectus is published on the website of the Shanghai Stock Exchange, the Company will publish relevant announcement(s) simultaneously on the website of the Hong Kong Stock Exchange for

- 1 -

the shareholders of the Company and potential investors to further review relevant financial information.

The key indicators of the Consolidated Financial Statements are as follows:

			RMB:0'000
	As at 30	As at 31
Item	September	December
	2019	2018	Flux %
Total asset	131,358.83	145,936.31	-9.99%
Total liabilities	44,933.93	46,607.86	-3.59%
Total equity	86,424.90	99,328.44	-12.99%
Total equity attributable to shareholders of
the Company	86,140.40	98,207.09	-12.29%

Item

Revenue Operating profit Profit before income tax Profit for the period

Profit attributable to shareholders of the Company

Profit attributable to shareholders of the Company after deduction of non- recurring profit or loss

Net cash generated from operating activities Net cash generated from investing activities Net cash generated from financing activities

Nine months ended
30 September	30 September
2019	2018	Flux %
62,485.03	48,908.49	27.76%
12,244.71	7,932.72	54.36%
12,143.12	7,879.37	54.11%
11,285.44	6,203.74	81.91%
11,833.60	8,401.99	40.84%
10,122.47	5,444.58	85.92%
13,710.89	7,761.96	76.64%
-1,929.92	-1,453.90	32.74%
-25,919.61	-952.95	2619.94%

- 2 -

Item	Nine months ended
		30 September
	30 September 2019	2018
Gain or loss on disposal of non-current assets	32.66	27.45
Government grants credited to profit or loss	275.57	2,551.43
Gain or loss on changes in fair values derived
from financial assets held for trading and
gain on disposal of financial assets held for
trading and available-for-sale financial
assets, except for effective hedging
operations related to the normal operations
of the company	819.83	987.45
Investment income from disposal of
subsidiaries	815.04	-
Other non-operating income and expenses
other than the above items	-101.59	-53.36
Total	1,841.51	3,512.98
Substract: income tax effect	125.67	481.80
Effect on non-controlling interests
(after tax)	4.70	73.77
Non-recurring profits and losses attributable
to shareholders of the Company	1,711.14	2,957.41

Potential investors and shareholders of the Company should exercise caution when dealing with the securities of the Company and should not unduly rely on such information.

By order of the Board

Wang Hai Bo

Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

31 October 2019

* For identification purpose only

- 3 -